Sanofi to acquire Inhibrx for approximately $1.7bn

Betsy Goodfellow | January 23, 2024 | News story | Business Services Inhibrx, Rare Diseases, Sanofi, acquisition 

Sanofi and Inhibrx, Inc have announced that they have entered into a definitive agreement for Sanofi to acquire Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx.

INBRX-101 is a human recombinant protein for the treatment of patients with Alpha-1 Antitrypsin Deficiency (AATD), allowing them to achieve normalisation of serum AAT levels with less frequent dosing.

The protein has already successfully completed a phase 1 trial, in which it demonstrated positive safety and pharmacokinetics results. Enrolment for the phase 2 trial is currently underway.

Under terms of the agreement, Sanofi will pay $30 per share, equaling an approximate total value of $1.7bn, as well as further milestone payments. New Inhibrx will retain non-INBRX-101 assets such as its immune-oncology pipeline, however Sanofi will gain an 8% equity stake in New Inhibrx.

Houman Ashrafian, head of research and development at Sanofi, commented: “The addition of INBRX-101 as a high potential asset to our rare disease portfolio reinforces our strategy to commit to differentiated and potential best-in-class products. With our expertise in rare diseases and growing presence in immune-mediated respiratory conditions, INBRX-101 will complement our approach to deploy R&D efforts in key areas of focus and address the needs of the underserved AATD patients and communities.”

Betsy Goodfellow

Related Content

BioGen to acquire Human Immunology Biosciences for $1.15bn

BioGen and Human Immunology Biosciences (HI-Bio) have announced that they have entered into a definitive …

Merck to acquire Mirus Bio for $600m

Merck has announced that it has signed a definitive agreement to acquire Mirus Bio for …

Sanofi, Formation Bio and OpenAI enter AI collaboration

Sanofi, Formation Bio and OpenAI have announced that they have entered into a collaboration with …

Latest content